| Emergence of promising therapies in diabetes mellitus. | |
| | |
MedLine Citation:
|
PMID: 20705952 Owner: NLM Status: In-Data-Review |
Abstract/OtherAbstract:
|
Diabetes mellitus (DM) results from defects in insulin secretion (type 1) or insulin resistance (type 2). Insulin is used to manage type 1 DM, and oral hypoglycemic agents are used to manage type 2 DM. These therapies are inconsistent in maintaining glycemic control and cause some severe adverse effects such as undue weight gain and hypoglycemia. New and appropriate therapies are needed to overcome these problems. Drugs that are in the pipeline include oral insulins for type 1 DM and incretin mimetics, incretin enhancers, gastric inhibitory peptides, amylin analogues, peroxisome proliferator-activated receptor-α/γ ligands, sodium-dependent glucose transporter inhibitors, and fructose 1,6-bisphosphatase inhibitors for type 2 DM. This article describes the mechanisms of action and relative advantages and disadvantages of the promising therapies. |
| | |
Authors:
|
Sindhu Akkati; Kishore Gnana Sam; Girish Tungha |
Publication Detail:
|
Type: Journal Article Date: 2010-08-12 |
Journal Detail:
|
Title: Journal of clinical pharmacology Volume: 51 ISSN: 1552-4604 ISO Abbreviation: J Clin Pharmacol Publication Date: 2011 Jun |
Date Detail:
|
Created Date: 2011-05-09 Completed Date: - Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 0366372 Medline TA: J Clin Pharmacol Country: United States |
Other Details:
|
Languages: eng Pagination: 796-804 Citation Subset: IM |
Affiliation:
|
Department of Pharmacy Practice, Manipal College of Pharmaceutical Sciences, Manipal University, Manipal, Karnataka, India 576104; e-mail: akkati.sindhureddy@gmail.com. |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
|
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Coadministration With Lopinavir and Ritonavir Decreases Exposure to BILR 355, a Nonnucleoside Revers...
Next Document: Functional impact of cancer-associated mutations in the tumor suppressor protein ING4.